Bone News and Research

RSS

Gentium presents abstract on Defibrotide at EBMT Annual Meeting

Gentium S.p.A.today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicenter study," was presented on Sunday, March 21, 2010, at the opening session of the European Blood and Marrow Transplantation 36th Annual Meeting in Vienna. The abstract received the esteemed Van Bekkum Award for the best abstract submitted to the physician's program. Dr. Selim Corbacioglu, Professor of Pediatrics, University of Regensburg (Germany) and Principal Investigator of the Pediatric Prevention trial, accepted the award and presented the final results of the study.

24 Mar 2010

Bioheart to open five centers to provide cell therapy procedures for congestive heart failure patients

Bioheart, Inc., announced today plans for establishing five Centers of Excellence in Latin America to provide its cell therapy procedures to patients suffering from congestive heart failure and peripheral arterial disease beginning next month, April 2010. Bioheart entered into its first agreement with a leading treatment facilitator, Regenerative Medicine Institute of Tijuana, Mexico. Therapies for CHF and PAD patients will be made available at the Hospital Angeles Tijuana, a fully equipped state-of–the-art private specialties hospital. This will be the first of five Centers of Excellence with four additional Centers to be announced in the coming months.

24 Mar 2010

Study reveals facial bone changes add to aging appearance

Facelifts and other wrinkle-reducing procedures have long been sought by people wanting to ward off the signs of aging, but new research suggests that it takes more than tightening loose skin to restore a youthful look.

24 Mar 2010

Coalition of international health organizations oppose compensation for bone marrow donors

Voicing concern about the potential impact on patient and donor safety, nine leading international health organizations have formed a coalition to oppose compensating people who provide bone marrow for transplantation.

23 Mar 2010

New, biodegradable biomaterial that promotes bone growth

Screws used in surgical operations are often made of titanium. They usually have to be removed after a while or replaced by new ones. A new biomaterial makes this unnecessary. It promotes bone growth and is biodegradable.

23 Mar 2010

You and your baby may need vitamin D supplementation says research

This report appeared in the respected Journal Pediatrics this week. There has been growing awareness regarding deficiency of Vitamin D in children and adults. This vitamin is important for healthy bones, immunity and other bodily processes. In children inadequacy of this vitamin in diet may lead to bone damage, rickets, repeated infections and heart disease in later life.

23 Mar 2010

Ipsen, GTx expand partnership for toremifene 80 mg

Ipsen today announced the expansion of their partnership for the development and commercialization of toremifene 80 mg for the reduction of fractures in men with advanced prostate cancer on androgen deprivation therapy (ADT) and toremifene 20 mg for the prevention of prostate cancer in high risk patients with High Grade Prostatic Intraepithelial Neoplasia lesions (HGPIN).

23 Mar 2010

Treatments for preventing hamstring injuries

A brand new systematic review into the research of hamstring injuries has revealed that not enough is known about the effectiveness of current prevention methods for one of the most common sports injuries.

22 Mar 2010

NYSE Amex grants Interleukin Genetics extension for regaining compliance

Interleukin Genetics, Inc. announced today that the Corporate Compliance Staff of the NYSE Amex LLC has granted the Company an extension to meet the Exchange's continued listing standards and become compliant. The Company will remain listed up to June 23, 2010, subject to periodic review by the Exchange staff during the extension period of progress towards the Company's plan to regain compliance.

22 Mar 2010

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology and hematology, and TopoTarget A/S, today announced that the first patient has been dosed in a National Cancer Institute -sponsored Phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or recurrent thymic malignancies.

22 Mar 2010

Gene implicated in JSRDs: UCD research team publishes new information

Researchers in University College Dublin (UCD) led by Conway Fellow, Dr Oliver Blacque have revealed new information about a gene implicated in Joubert syndrome and related cerebellar disorders (JSRDs) that are characterised by blindness, bone abnormalities, cystic kidneys, developmental delay and loss of muscle tone and control. The findings from this research, which is funded by Science Foundation Ireland, have been published today in a leading science journal, Journal of Cell Biology.

22 Mar 2010

Cancer radiotherapy can increase risk of cardiovascular disease later in life

For an as yet unknown reason, cancer radiotherapy can increase the risk of cardiovascular disease later in life, a problem that is growing as more and more people survive their cancer diagnosis. New research from Karolinska Institutet now suggests that sustained inflammation induced by post-radiotherapy changes in the gene expression in the arteries could be the cause.

22 Mar 2010

Asuragen appoints BMD as exclusive distributor of Signature Oncology Products in France

Asuragen, Inc., a leader in the development of molecular diagnostics, announced today the appointment of Biomedical Diagnostics SA, a leading medical diagnostic company in Europe, as its exclusive distributor of Signature® Oncology Products in France. Asuragen’s Signature Oncology Portfolio comprises multiplex assays for the detection of mutations in solid and hematologic malignancies.

22 Mar 2010

Scientists identify new growth factor that stimulates expansion of hematopoietic stem cells

Scientists at Duke University Medical Center have identified a new growth factor that stimulates the expansion and regeneration of hematopoietic (blood-forming) stem cells in culture and in laboratory animals. The discovery, appearing in the journal Nature Medicine, may help researchers overcome one of the most frustrating barriers to cellular therapy: the fact that stem cells are so few in number and so stubbornly resistant to expansion.

22 Mar 2010

$Stress fracture: Causes and treatment strategies$

Stress fracture: Causes and treatment strategies

When pain from increased physical activity doesn’t go away in a couple of days, the cause could be a stress fracture. The March issue of Mayo Clinic Health Letter covers these tiny, partial bone fractures, why they occur and how they are treated.

20 Mar 2010

Bovie Medical receives FDA marketing clearance for BOSS bipolar sintered steel coagulation device

Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced the Company received clearance from the Food and Drug Administration (FDA) to market its proprietary BOSS™ bipolar sintered steel coagulation device. The BOSS™ is the latest device based on Bovie’s saline enhanced sintered steel technology.

19 Mar 2010

Propeller tears right arm, UT Southwestern Medical Center surgeon re-attaches

"The propeller cut through the skin, muscle, tendons and bone and had removed portions of the bone," he recalled. "Basically, she had severed her arm, and it was attached only by some skin, tendon, nerve and artery."

19 Mar 2010

Stemedica files IND for trial using allogeneic mesenchymal bone marrow cells in patients with ischemic stroke

Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it has filed an Investigative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial. The trial will assess the safety, tolerability and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.

19 Mar 2010

Robertson Foundation commits $10.2M for Duke Medicine's cell therapy research

A $10.2 million commitment from the Robertson Foundation to create a state-of-the-art Translational Cell Therapy Center (TCTC) will advance Duke Medicine's pioneering cell therapy research and treatment programs for children and adults with cancer, cerebral palsy, stroke and brain injuries suffered at birth.

19 Mar 2010

Having lower TSH levels while taking thyroxine replacement is not detrimental to health, says study

New research shows that it may be safe for patients taking thyroxine replacement to have low but not suppressed thyroid stimulating hormone (TSH) levels. The research, presented at the Society for Endocrinology BES meeting in Manchester, shows for the first time that it may be safe for patients to take slightly higher doses of thyroxine than are currently recommended.

18 Mar 2010